ST. LOUIS, Nov. 26, 2024 (GLOBE NEWSWIRE) — Stereotaxis STXS, a pioneer and world chief in surgical robotics for minimally invasive endovascular intervention, at present introduced that David Fischel, Chairman and CEO, will take part within the Piper Sandler 36th Annual Healthcare Convention.
Mr. Fischel will ship a proper presentation on Stereotaxis’ know-how and development technique on Thursday, December 5, 2024, at 2:00 pm ET. Mr. Fischel shall be accessible for one-on-one conferences that very same day.
“That is an thrilling interval for Stereotaxis and we sit up for sharing our progress in realizing a beautiful development technique,” stated Mr. Fischel. “We admire the chance to have interaction with traders on the Piper Sandler convention.”
About Stereotaxis
Stereotaxis STXS is a pioneer and world chief in modern surgical robotics for minimally invasive endovascular intervention. Its mission is the invention, growth and supply of robotic methods, devices, and data options for the interventional laboratory. These improvements assist physicians present unsurpassed affected person care with robotic precision and security, broaden entry to minimally invasive remedy, and improve the productiveness, connectivity, and intelligence within the working room. Stereotaxis know-how has been used to deal with over 150,000 sufferers throughout the US, Europe, Asia, and elsewhere. For extra data, please go to www.Stereotaxis.com.
This press launch consists of statements that will represent “forward-looking” statements, often containing the phrases “imagine”, “estimate”, “undertaking”, “anticipate” or related expressions. Ahead-looking statements inherently contain dangers and uncertainties that might trigger precise outcomes to vary materially. Components that might trigger or contribute to such variations embrace, however should not restricted to, the Firm’s capability to handle bills at sustainable ranges, acceptance of the Firm’s merchandise within the market, the impact of worldwide financial circumstances on the flexibility and willingness of consumers to buy its know-how, aggressive elements, modifications ensuing from healthcare coverage, dependence upon third-party distributors, timing of regulatory approvals, the influence of pandemics or different disasters, and statements referring to our current acquisition of APT, together with any advantages anticipated from the acquisition, and different dangers mentioned within the Firm’s periodic and different filings with the Securities and Alternate Fee. By making these forward-looking statements, the Firm undertakes no obligation to replace these statements for revisions or modifications after the date of this launch. There will be no assurance that the Firm will acknowledge income associated to its buy orders and different commitments as a result of a few of these buy orders and different commitments are topic to contingencies which are outdoors of the Firm’s management and could also be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Government Officer
Kimberly Peery
Chief Monetary Officer
314-678-6100
[email protected]
Market Information and Knowledge delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
